Praxis Precision Medicines, INC Schedule 13G passive stakes
NASDAQ
SCHEDULE 13G/A: Venrock Healthcare Capital Partners Group Amends Passive Stake in Praxis Precision Medicines to 6.1%
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in Praxis Precision Medicines, Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Perceptive Advisors and Joseph Edelman Disclose 9.5% Stake in Praxis Precision Medicines
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a combined beneficial ownership of 9.5% in Praxis Precision Medicines, Inc., totaling 1,829,735 shares.
NASDAQ
Point72 Asset Management, along with affiliated entities and founder Steven A. Cohen, have disclosed a combined beneficial ownership of 6.3% in Praxis Precision Medicines, Inc., as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Cormorant Asset Management Updates Significant Stake in Praxis Precision Medicines, Holding Over 9% of Common Stock
Cormorant Asset Management, LP and Bihua Chen have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.08% in Praxis Precision Medicines, Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G: Morgan Stanley Discloses Significant Passive Stake in Praxis Precision Medicines, Inc.
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 6.2% of Praxis Precision Medicines, Inc.'s common stock as of December 31, 2024.